BioLight Life Sciences (BioLight Life Sciences) EBITDA Margin % : -25,313.64% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is BioLight Life Sciences EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. BioLight Life Sciences's EBITDA for the six months ended in Dec. 2023 was $-5.57 Mil. BioLight Life Sciences's Revenue for the six months ended in Dec. 2023 was $0.02 Mil. Therefore, BioLight Life Sciences's EBITDA margin for the quarter that ended in Dec. 2023 was -25,313.64%.

BioLight Life Sciences EBITDA Margin % Historical Data

The historical data trend for BioLight Life Sciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLight Life Sciences EBITDA Margin % Chart

BioLight Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-43,962.50

-34,400.00

-13,118.75

-22,651.61

BioLight Life Sciences Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial															-	-62,150.00	-5,706.67	-16,133.33	-25,313.64

Competitive Comparison of BioLight Life Sciences's EBITDA Margin %

For the Biotechnology subindustry, BioLight Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLight Life Sciences's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLight Life Sciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where BioLight Life Sciences's EBITDA Margin % falls into.

BioLight Life Sciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

BioLight Life Sciences's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-7.022	/	0.031
	=	-22,651.61 %

BioLight Life Sciences's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-5.569	/	0.022
	=	-25,313.64 %

BioLight Life Sciences (NAS:BOLT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

BioLight Life Sciences EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of BioLight Life Sciences's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLight Life Sciences (BioLight Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLight Life Sciences Ltd (NAS:BOLT) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

BOLT:Israel

Address

Kiryat Atidim, Building 7, Entrance 1, 2nd Floor, Tel-Aviv, ISR, 6158101

Website

http://www.bio-light.co.il

BioLight Life Sciences Ltd is an emerging global ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.